Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

por Grimm, Sabine E., Witlox, Willem, Wolff, Robert, Chalker, Annette, Hiligsmann, Mickael, Wijnen, Ben, Ahmadu, Charlotte, Ryder, Steve, Armstrong, Nigel, Duffy, Steven, Syndikus, Isabel, Kleijnen, Jos, Joore, Manuela A.
Publicado 2022

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

por Lindeman, Geoffrey J., Fernando, Tharu M., Bowen, Rebecca, Jerzak, Katarzyna J., Song, Xinni, Decker, Thomas, Boyle, Frances, McCune, Steve, Armstrong, Anne, Shannon, Catherine, Bertelli, Gianfilippo, Chang, Ching-Wei, Desai, Rupal, Gupta, Kushagra, Wilson, Timothy R., Flechais, Aulde, Bardia, Aditya
Publicado 2022

Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

por Grimm, Sabine E., Witlox, Willem, Wolff, Robert, Chalker, Annette, Hiligsmann, Mickael, Wijnen, Ben, Ahmadu, Charlotte, Ryder, Steve, Armstrong, Nigel, Duffy, Steven, Syndikus, Isabel, Kleijnen, Jos, Joore, Manuela A.
Publicado 2021